OTA's Gibbons: `Important New Realities' Face U.S. Science

More than a decade later, it seems that Gibbons has met the challenge. He presides over a $21 million budget and a 150-member staff of scientists and technologists who, with the help of outside experts, produce more than two dozen major reports each year, conduct hundreds of briefings for federal officials, and appear regularly before Congress and at scientific meetings and conferences. A recent report from the Carnegie Commission on Science, Technology, and Government cites the agency's "sol

Written byJeffrey Mervis
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

More than a decade later, it seems that Gibbons has met the challenge. He presides over a $21 million budget and a 150-member staff of scientists and technologists who, with the help of outside experts, produce more than two dozen major reports each year, conduct hundreds of briefings for federal officials, and appear regularly before Congress and at scientific meetings and conferences. A recent report from the Carnegie Commission on Science, Technology, and Government cites the agency's "solid reputation for in-depth analysis of major issues." The report says OTA's work is "widely used and appreciated," and suggests it collaborate more closely with the executive branch as well as with legislators.

The 62-year-old Gibbons already does those things, but quietly. He says he prefers having his staff testify, because "committees would rather hear it from the people who really know that subject, not some guy with window dressing." And he says ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies